PubMedCrossRef 9. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability MAPK inhibitor of a microemulsion-based formulation (Neoral). Drugs. 1995;50:924–41.PubMedCrossRef
10. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C2 monitoring: a review. Transplantation. 2002;73:S3–11.PubMedCrossRef 11. Tanaka H, Nakahata T, Ito E. Single-dose daily administration of cyclosporin A for relapsing nephrotic syndrome. Pediatr Nephrol. 2004;19:1055–8.PubMedCrossRef 12. Takeda A, Horike K, Onoda H, Ohtsuka Y, Yoshida A, Uchida K, et al. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Nephrology. 2007;12:197–204.PubMedCrossRef 13. Shirai S, Yasuda T, Tsuchida H, Kuboshima S, Konno Y, Shima Y, et al. Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. Clin Exp Nephrol. 2009;13:123–9.PubMedCrossRef
14. Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. The pathology annual no. 3. New York: Appleton-Century-Crofts; 1968. p. 145–86. 15. Cattran DC, Feehally J, Cook HT, Fervenza FC, Floege J, Gipson DS, et al. KDIGO clinical Transmembrane Transporters inhibitor practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:S139–274. 16. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Protein kinase N1 workshop recommendations. Kidney Int. 2007;72:1429–47.PubMedCrossRef 17. Matsuo S, Imai E, Saito T, Taguchi T, Yokoyama H, Narita I. Guidelines for the treatment
of nephrotic syndrome. Nihon Jinzo Gakkai Shi. 2011;53:78–122. 18. Rostoker G, Belghiti D, BenMaadi A, Rémy P, Lang P, Weil B, et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron. 1993;63:335–41.PubMedCrossRef 19. Frische L, Budde K, Färber L, Charissé G, Kunz R, Gaedeke J, et al. Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant. 1999;14:1036–8.CrossRef 20. Iida H, Naito T, Sakai N, Aoki S. Effect of cyclosporine therapy on idiopathic membranous nephropathy presented with refractory nephrotic syndrome. Clin Exp Nephrol. 2000;4:81–5.CrossRef 21. Rifai N, Chao FF, Pham Q, Thiessen J, Soldin SJ. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. Clin Biochem. 1996;29:149–55.PubMedCrossRef 22. Sugioka N, Kokuhu T, Okamoto M, Yoshimura N, Ito Y, Shibata N, et al. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients. J Pharm Pharmacol. 2006;58:1193–200.PubMedCrossRef 23. Brunet M, Campistol JM, Millán O, Vidal E, Esforzado N, Rojo I, et al.